HEMATOPOIESIS - BRIEF REPORT

Phase I Clinical Study of Eltrombopag, an Oral, Non-peptide Thrombopoietin Receptor Agonist

Julian M. Jenkins, Daphne Williams, Yanli Deng, Joanne Uhl, Valerie Kitchen, David Collins, Connie L. Erickson-Miller.

Julian M Jenkins – designed research, analyzed data, wrote the paper
Daphne Williams – collected data, analyzed data
Yanli Deng – collected data, analyzed data
Joanne Uhl – designed research
Valerie Kitchen – designed research, medical advisor
David Collins - collected data, analyzed data
Connie Erickson-Miller – designed research, analyzed data, wrote the paper

1. All of the authors (JMJ, DW, YD, JU, VK, DC, CEM) have declared a financial interest in a company whose (potential) product was studied in the present work.
2. Several of the authors (CEM, DC) have declared a financial interest in a competitor of a company whose (potential) product was studied in the present work.
3. All of the authors (JMJ, DW, YD, JU, VK, DC, CEM) are employed by a company or a competitor of a company (X company) whose (potential) product was studied in the present work.
4. Several of the authors (JMJ, CEM) hold a patent related to the work that is described in the present study.

This study was supported by research funding from GlaxoSmithKline

Reprints:

Julian Jenkins, GlaxoSmithKline, 1250 South Collegeville Rd, Collegeville, PA 19426.
email: julian.m.jenkins@gsk.com
Abstract

Eltrombopag (SB-497115) is a first in class, oral, small molecule, non-peptide agonist of the thrombopoietin receptor (TpoR), being developed as a treatment for thrombocytopenia of various etiologies. In this phase I placebo-controlled clinical trial in 73 healthy male subjects, eltrombopag was administered as once daily oral capsules for 10 days at doses of 5, 10, 25, 30, 50 and 75mg. The pharmacokinetics of eltrombopag were dose dependent and linear, and eltrombopag increased platelet counts in a dose dependent manner. There were no apparent differences in the incidence or severity of adverse events in subjects receiving active or placebo study medication. These observations indicate that eltrombopag is a once daily, oral TpoR agonist with demonstrated thrombopoietic activity in human subjects, encouraging further studies in patients with thrombocytopenia.

Introduction

Thrombocytopenia, a reduction in platelet count, is a frequent finding in several medical disorders, such as aplastic anemia, some infections, myelodysplasia, idiopathic thrombocytopenic purpura (ITP) or chronic liver disease. Another etiology of clinically significant thrombocytopenia is the use of myelosuppressive chemotherapy or interferon antiviral treatment. Currently, there is an unmet need for thrombopoietic agents for the treatment of thrombocytopenia.

Thrombopoietin (Tpo) is the key cytokine involved in thrombopoiesis, and is the endogenous ligand for the thrombopoietin receptor (TpoR) that is expressed on the surface of megakaryocytes, and megakaryocytic precursors [1,2]. Binding of Tpo to its receptor triggers the activation of the JAK-STAT pathway, leading to changes in gene expression that promote progression along the megakaryocytic pathway, ultimately leading to the release of platelets into the peripheral circulation [3-5].

Administration of recombinant Tpo to rodents, primates and humans leads to significant increases in circulating platelet levels [9-14]. However, due to immunogenicity issues, forms of recombinant Tpo are no longer in clinical trials. Other molecules with Tpo-like activities are in clinical trials to treat thrombocytopenic patients [1, 15]. Peptidyl thrombopoietic agents, such as AMG-531, have been shown to increase platelet counts in healthy volunteers and patients with ITP, however, they are not orally bioavailable and they have the potential to be immunogenic. Non-peptide, small molecule, TpoR agonists can be orally bioavailable and are less likely to induce an immune or injection site response [15-19].

In this report we describe a first-in-class, small molecule, non-peptide, orally bioavailable thrombopoietin receptor agonist, eltrombopag (SB-497115). Preclinical studies have shown that eltrombopag interacts selectively with TpoR, thereby activating intracellular signal transduction pathways leading to increased proliferation and differentiation of human bone marrow progenitor cells [20]. Platelet counts increased when eltrombopag was administered as an oral suspension to chimpanzees [21]. Therefore, eltrombopag may be considered an oral platelet growth factor.
This phase I clinical trial in healthy human subjects, was conducted to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of eltrombopag, when administered as a once daily oral dose.

Methods

Seventy three healthy male subjects were randomized into 6 groups of 12 subjects to receive active eltrombopag or placebo (9 active : 3 placebo) as oral capsules once daily for 10 days at doses of 5, 10, 20, 30, 50 or 75 mg. The criteria for enrolment included no previous history of DVT, thrombocytopenia, abnormal platelet function, heart attack, stroke or heart murmur, and all clinical laboratory tests should be within the normal range at screening. Subjects were blinded to study medication, however, the investigator and sponsor were not blinded. One subject in the 50 mg cohort withdrew for personal reasons and was replaced.

All subjects provided written, informed consent to participate in the study. The Hammersmith Medicine Research at the Central Middlesex Hospital Institutional Review Board provided formal approval for the study, which was conducted in accordance with good clinical practice, all known regulatory requirements, and the revised Declaration of Helsinki.

Intensive safety, tolerability, pharmacokinetic, and pharmacodynamic assessments were made throughout the study. Safety assessments included electrocardiography, vital signs, serum chemistry, hematology, urinalysis and adverse event reporting. Plasma samples for eltrombopag concentration-time analysis were collected after the administration of a single dose and at several time points during the 10 day repeat dose phase. Eltrombopag plasma concentration-time data were analyzed using actual collection times recorded during the study. Pharmacodynamic parameters included platelet count, platelet activation and aggregation. Platelet activation was assessed using a Becton Dickinson flow cytometer to measure the percentage of PAC-1 and P-selectin positive platelets, and a Helena Labs PACKS-4 system was used to measure platelet aggregation in the presence of ADP as an agonist.

Results & Discussion

In this phase I placebo-controlled clinical trial, eltrombopag was administered as oral capsules to healthy male subjects at doses of 5-75 mg once daily for 10 days. There was a similar pattern of age (mean 27.5y), height (1.8m) and weight (79.8kg) across the seven dose cohorts. The mean baseline platelet count in the 73 subjects was 239 x10^9/L (range 134 – 347).

Pharmacodynamic Assessments

None of the 9 subjects in the 5mg or 10mg dose groups, 1/9 subject in the 20mg dose group, 6/9 subjects in the 30mg dose group and 9/9 in the 50mg and 75mg dose groups achieved a platelet count >20% above baseline. In the 5mg, 10mg and 20mg dose groups the 95% CI for each active versus placebo comparison encompassed unity. The mean increases in platelet count for the 30, 50, and 75 mg dose levels were 24.1 % (257.6 to 319.6 x10^9/L), 42.9 % (254.3 to 363.4 x10^9/L), and 50.4 % (235.9 to 354.9 x10^9/L).
respectively, shown as a mean (SD) ratio to baseline in Figure 1A. The highest individual platelet count recorded was 457 x10^9/L, an increase of 175 x10^9/L from baseline on day 16 at the 50mg dose.

A consistent increase in platelet count started after 8 days of repeat dosing with eltrombopag, and the time from first dose to peak platelet count was 16 days. By Day 22, (12 days after the last dose of eltrombopag) platelet count had returned to baseline values (Figure 1B). These data are consistent with published platelet count profiles observed after the administration of recombinant MGDF in humans [14], therefore, the pharmacodynamic effects of eltrombopag likely reflect the normal kinetics of thrombopoiesis. Furthermore, there was no evidence of rebound thrombocytopenia, whereby platelet counts did not go below baseline levels following discontinuation of treatment.

Platelet function, as measured by platelet aggregation and activation was not affected by the administration of eltrombopag, with similar results observed in subjects administered placebo and active study medication. For example, the mean percentage of PAC-1 positive cells in the placebo treated subjects was 7.5 on day 1 and 11.7 on day 12, and in the 75mg treated subjects was 4.3 on day 1 and 4.8 on day 12. Platelet aggregation was reported as normal in all 73 subjects after receiving active or placebo treatment.

Pharmacokinetic Assessments

Confirming preclinical data, eltrombopag was orally bioavailable when administered as oral capsules to healthy male subjects. The pharmacokinetics of eltrombopag were dose dependent and linear. In the 75mg cohort, the mean Cmax was 7.3 ug/mL (15% CV) at approximately 2.5–5 h after dosing, with a mean AUC of 79.0 ug.hr/mL (23% CV). T1/2 averaged >12 h on Day 10 across all doses, with the exception of the 5 mg dose (9h). There was no accumulation of eltrombopag after once daily dosing at 5 mg and 10 mg, but there was approximately 40–50% accumulation at the 20 mg, 30 mg, 50 mg, and 75 mg dose levels.

Safety and Tolerability Assessments

Adverse events (AEs) did not differ among the normal human subject treatment groups, including placebo and were not dose related (Table 1). There were no changes in vital signs, laboratory tests, or ECGs, that were clinically significant, or could reasonably be attributed to study medication. Overall, 10 days administration of 5–75 mg eltrombopag was safe and well-tolerated, as judged by laboratory safety tests, blood pressure, heart rate, ECG, and AE. There were no serious AEs reported during the study.

In summary, eltrombopag represents the first in a class of orally bioavailable, small molecule, non-peptide thrombopoietin receptor agonists. The pharmacodynamic, pharmacokinetic and safety profile demonstrated in this study supports further clinical studies in thrombocytopenic patients.
Table 1. Most frequently reported adverse events reported in the Phase I study of eltrombopag in healthy male subjects.

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>5mg</th>
<th>10mg</th>
<th>20mg</th>
<th>30mg</th>
<th>50mg</th>
<th>75mg</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>Practice</td>
</tr>
<tr>
<td>Abdominal pain/cramp</td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sore throat</td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tiredness</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loose stools</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Minor nose bleed</td>
<td>1</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bruise</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Subjects exposed</strong></td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>10</td>
<td>9</td>
<td>18</td>
</tr>
</tbody>
</table>

Others adverse events include (<1): blurred vision, indigestion, dermatitis

**FIGURE LEGENDS**

**Figure 1A.**
Platelet response in healthy male subjects following oral dosing with eltrombopag (once per day) for 10 days. Increases are apparent at 30, 50 and 75 mg. (Mean and 1xSD)

**Figure 1B.**
Kinetics of platelet response in healthy male subjects following 10 days oral dosing of 75 mg eltrombopag. The platelet number began rising at 5 days and peaked at day 15. (Mean and 1xSD)
Figure 1A

Platelets (ratio to baseline)

Eltrombopag dose

placebo 5mg 10mg 20mg 30mg 50mg 75mg

For personal use only.on April 15, 2017. By guest

www.bloodjournal.org From
Figure 1B

![Platelet Count (x1000) vs. Study Day Graph]

- The graph shows the platelet count (x1000) over study days.
- The x-axis represents the study days, ranging from 1 to 28.
- The y-axis represents the platelet count (x1000), ranging from 150 to 400.
- The data points show an overall increase in platelet count from day 1 to day 16, followed by a decrease on day 18, and a further decrease towards day 28.
References


Phase I clinical study of eltrombopag, an oral, non-peptide thrombopoietin receptor agonist

Julian M Jenkins, Daphne Williams, Yanli Deng, Joanne Uhl, Valerie Kitchen, David Collins and Connie L Erickson-Miller